CA3264385A1 - NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY - Google Patents
NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPYInfo
- Publication number
- CA3264385A1 CA3264385A1 CA3264385A CA3264385A CA3264385A1 CA 3264385 A1 CA3264385 A1 CA 3264385A1 CA 3264385 A CA3264385 A CA 3264385A CA 3264385 A CA3264385 A CA 3264385A CA 3264385 A1 CA3264385 A1 CA 3264385A1
- Authority
- CA
- Canada
- Prior art keywords
- minigastrin
- imaging
- novel
- receptor binding
- binding molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22196630 | 2022-09-20 | ||
| EP22196630.2 | 2022-09-20 | ||
| PCT/EP2023/063469 WO2024061483A1 (en) | 2022-09-20 | 2023-05-19 | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3264385A1 true CA3264385A1 (en) | 2024-03-28 |
Family
ID=83994946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3264385A Pending CA3264385A1 (en) | 2022-09-20 | 2023-05-19 | NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP4590347A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025532619A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250073200A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119907695A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023345654A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3264385A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL319379A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025003151A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024061483A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12642876B1 (en) | 2025-10-30 | 2026-06-02 | Perspective Therapeutics, Inc. | Cholecystokinin-2 receptor targeted compounds and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3412303A1 (en) * | 2017-06-08 | 2018-12-12 | Medizinische Universität Innsbruck | Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy |
| KR20240027896A (ko) * | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
-
2023
- 2023-05-19 CA CA3264385A patent/CA3264385A1/en active Pending
- 2023-05-19 IL IL319379A patent/IL319379A/en unknown
- 2023-05-19 EP EP23727562.3A patent/EP4590347A1/en active Pending
- 2023-05-19 WO PCT/EP2023/063469 patent/WO2024061483A1/en not_active Ceased
- 2023-05-19 JP JP2025515980A patent/JP2025532619A/ja active Pending
- 2023-05-19 AU AU2023345654A patent/AU2023345654A1/en active Pending
- 2023-05-19 KR KR1020257012384A patent/KR20250073200A/ko active Pending
- 2023-05-19 EP EP25193071.5A patent/EP4631959A3/en active Pending
- 2023-05-19 CN CN202380067423.2A patent/CN119907695A/zh active Pending
-
2025
- 2025-03-18 MX MX2025003151A patent/MX2025003151A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250073200A (ko) | 2025-05-27 |
| CN119907695A (zh) | 2025-04-29 |
| JP2025532619A (ja) | 2025-10-01 |
| AU2023345654A1 (en) | 2025-02-27 |
| WO2024061483A1 (en) | 2024-03-28 |
| MX2025003151A (es) | 2025-04-02 |
| EP4590347A1 (en) | 2025-07-30 |
| IL319379A (en) | 2025-05-01 |
| EP4631959A3 (en) | 2025-12-17 |
| EP4631959A2 (en) | 2025-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL128003A (en) | MULTISPECIFIC BINDING MOLECULES COMPRISING A BINDING DETERMINANT WHICH BINDS AN FCalpha RECEPTOR | |
| MX2010001378A (es) | Uso terapeutico de anticuerpos del receptor anti-tweak. | |
| WO2002099051A3 (en) | Nits as modifiers of the p53 pathway and methods of use | |
| SA523442921B1 (ar) | جزيئات ربط علاجية | |
| MX2007006102A (es) | Agentes anti-cancer de union a tubulina y profarmacos de los mismos. | |
| IL319379A (en) | Novel cholecystokinin 2 receptor-binding molecules derived from minigastrin for imaging and targeted radiotherapy | |
| HK40122619A (en) | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy | |
| EP4142737A4 (en) | BINDING AGENTS AND USES THEREOF FOR CENTRAL NERVOUS SYSTEM DEPRESSION | |
| ZA202309150B (en) | Antibody against nkp46 and application of antibody | |
| IL320410A (en) | Combination therapy involving bispecific antibodies containing an NRP1 binding domain | |
| MX2007016469A (es) | Metodos de tratamiento utilizando ansamicinas de hidroquinona. | |
| WO2021011673A3 (en) | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease | |
| AU2024221616A1 (en) | Antibody-drug conjugate for cancer treatment | |
| WO2023150510A3 (en) | Car and polyspecific binding molecules targeting solid tumors | |
| AU2022299351B2 (en) | Nad-augmentation therapy for parkinson's disease | |
| CA3263784A1 (en) | TRANSFERRIN RECEPTOR BINDING PROTEINS FOR THE TREATMENT OF BRAIN TUMORS | |
| IL317689A (en) | Binding molecules for cancer treatment | |
| AU2003221878A1 (en) | G-protein coupled receptor ligands and methods | |
| EP4085908A4 (en) | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION | |
| CA3284262A1 (en) | Compositions for treating parkinson's disease and qualitative assessment thereof | |
| GB202306865D0 (en) | Conjugate and composition for treating cancer | |
| GB202400705D0 (en) | Receptor binding molecules | |
| CA3282171A1 (en) | Pharmaceutical composition for treating tumors | |
| HK40120229A (en) | Anti-folate receptor conjugate cancer therapy | |
| CA3290371A1 (en) | B7-h4 therapeutic binding molecules for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20250206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250501 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250513 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250513 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250513 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250513 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260422 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260422 |